Recent Updates — CLDWW

Calidi Biotherapeutics received a notice from NYSE American on September 21, 2026, stating it is not in compliance with the stockholders’ equity continued listing standard. The exchange requires $4.0 million in equity for companies reporting losses in three of four recent fiscal years; Calidi reported $3.1 million as of June 30, 2026. The company must submit a compliance plan by October 21, 2026, to regain compliance by March 21, 2028. Failure to submit or accept the plan triggers delisting proceedings. Trading continues under symbol CLDI with a “.BC” indicator. Calidi Biotherapeutics is a biotechnology company developing targeted genetic medicines using its RedTail platform.

Calidi Biotherapeutics reported a net loss of $4.2 million ($2.94 per share) for the second quarter ended June 30, 2026, compared to a $5.7 million loss in the prior year period. The company received positive pre-IND feedback from the U.S. FDA for its lead candidate CLD-401, aligning on development strategy toward first-in-human dosing in Q1 2027. Additionally, Calidi presented new data on its RedTail platform at ASCO and added Corsee Sanders to its Board of Directors. General and administrative expenses decreased by $1.5 million (48%) year-over-year to $1.6 million. The company held $4.1 million in cash as of June 30, 2026. Calidi Biotherapeutics is a biotechnology company pioneering the development of targeted genetic medicines using its proprietary RedTail platform.

Calidi Biotherapeutics, Inc. effected a reverse stock split of its common stock at a ratio of 1-for-16 to increase the per-share trading price and support continued listing on NYSE American. The split became effective on July 30, 2026, with split-adjusted trading commencing on July 31, 2026. Fractional shares were rounded up to the nearest whole share without cash payment. Post-split, approximately 2,445,396 Voting Common Stock and 9,375 Non-Voting Common Shares are outstanding out of 330 million authorized shares. Calidi Biotherapeutics operates in the biotechnology industry, developing immunotherapies for cancer treatment.

Calidi Biotherapeutics, Inc. entered into a new lease agreement for 9,038 square feet of office and laboratory space in San Diego, California, starting October 1, 2026, for a 44-month term. The company will terminate its existing lease effective September 30, 2026, and expects to save approximately $1.1 million per year in rent and facility-related expenses. Calidi Biotherapeutics, Inc. is a biotechnology company focused on oncolytic virotherapy for-profit.